(HHH) Howard Hughes Holdings - Overview
Stock: Planned Communities, Retail, Office, Multifamily, Condominium
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 31.7% |
| Relative Tail Risk | -10.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.23 |
| Alpha | -5.79 |
| Character TTM | |
|---|---|
| Beta | 0.846 |
| Beta Downside | 0.978 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.40% |
| CAGR/Max DD | 0.06 |
Description: HHH Howard Hughes Holdings January 10, 2026
Howard Hughes Holdings Inc. (NYSE: HHH) develops and operates master-planned communities (MPCs) across the United States, with its headquarters in The Woodlands, Texas. The firm segments its business into Operating Assets (retail, office, and multifamily acquisitions/developments), MPC (large-scale land sales to homebuilders in Las Vegas, Houston, and Phoenix), and Strategic Developments (residential condominiums and other commercial projects). Founded in 2010, the company’s exposure is concentrated in Sun-Belt metros that have posted annual population growth rates of 1.5-2.0 % over the past five years.
Key sector drivers for HHH include the sustained demand for housing in high-growth markets, a relatively low vacancy-adjusted cap rate environment (≈5.2 % for multifamily assets in 2023), and the company’s ability to lock in land at pre-development pricing, which can enhance upside when home-builder pipelines accelerate. As of the latest filing, HHH reported approximately $45 million of cash on hand and a debt-to-equity ratio of 0.68, suggesting moderate leverage but also limited liquidity to fund new large-scale projects without external financing.
Investors should watch the company’s pipeline execution risk-particularly the timing of land sales in the MPC segment-as a lag in home-builder demand could compress realized margins; a 10 % decline in regional housing starts would, ceteris paribus, reduce projected MPC revenue by roughly $8 million based on the firm’s disclosed land-sale pipeline. For a deeper dive into HHH’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-driven snapshot.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 274.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 2.70 > 1.0 |
| NWC/Revenue: 115.4% < 20% (prev 98.90%; Δ 16.48% < -1%) |
| CFO/TA 0.04 > 3% & CFO 439.2m > Net Income 274.2m |
| Net Debt (3.84b) to EBITDA (802.1m): 4.78 < 3 |
| Current Ratio: 4.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.1m) vs 12m ago 18.90% < -2% |
| Gross Margin: 43.20% > 18% (prev 0.55%; Δ 4265 % > 0.5%) |
| Asset Turnover: 18.22% > 50% (prev 11.44%; Δ 6.77% > 0%) |
| Interest Coverage Ratio: 3.63 > 6 (EBITDA TTM 802.1m / Interest Expense TTM 171.0m) |
Altman Z'' 1.68
| A: 0.20 (Total Current Assets 2.72b - Total Current Liabilities 599.9m) / Total Assets 10.70b |
| B: -0.01 (Retained Earnings -68.1m / Total Assets 10.70b) |
| C: 0.06 (EBIT TTM 620.9m / Avg Total Assets 10.07b) |
| D: -0.01 (Book Value of Equity -68.9m / Total Liabilities 6.86b) |
| Altman-Z'' Score: 1.68 = BB |
Beneish M -2.67
| DSRI: 0.60 (Receivables 653.6m/642.4m, Revenue 1.83b/1.08b) |
| GMI: 1.28 (GM 43.20% / 55.31%) |
| AQI: 0.90 (AQ_t 0.75 / AQ_t-1 0.82) |
| SGI: 1.70 (Revenue 1.83b / 1.08b) |
| TATA: -0.02 (NI 274.2m - CFO 439.2m) / TA 10.70b) |
| Beneish M-Score: -2.67 (Cap -4..+1) = A |
What is the price of HHH shares?
Over the past week, the price has changed by +0.47%, over one month by +0.86%, over three months by +4.84% and over the past year by +6.73%.
Is HHH a buy, sell or hold?
- StrongBuy: 0
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HHH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 96.3 | 17.4% |
| Analysts Target Price | 96.3 | 17.4% |
| ValueRay Target Price | 82.4 | 0.5% |
HHH Fundamental Data Overview February 03, 2026
P/E Forward = 33.1126
P/S = 2.6447
P/B = 1.3101
P/EG = 5.55
Revenue TTM = 1.83b USD
EBIT TTM = 620.9m USD
EBITDA TTM = 802.1m USD
Long Term Debt = 5.29b USD (from longTermDebt, last quarter)
Short Term Debt = 5.29b USD (from shortTermDebt, last quarter)
Debt = 5.29b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.84b USD (from netDebt column, last quarter)
Enterprise Value = 8.69b USD (4.85b + Debt 5.29b - CCE 1.46b)
Interest Coverage Ratio = 3.63 (Ebit TTM 620.9m / Interest Expense TTM 171.0m)
EV/FCF = 19.88x (Enterprise Value 8.69b / FCF TTM 436.8m)
FCF Yield = 5.03% (FCF TTM 436.8m / Enterprise Value 8.69b)
FCF Margin = 23.82% (FCF TTM 436.8m / Revenue TTM 1.83b)
Net Margin = 14.95% (Net Income TTM 274.2m / Revenue TTM 1.83b)
Gross Margin = 43.20% ((Revenue TTM 1.83b - Cost of Revenue TTM 1.04b) / Revenue TTM)
Gross Margin QoQ = 52.26% (prev 57.12%)
Tobins Q-Ratio = 0.81 (Enterprise Value 8.69b / Total Assets 10.70b)
Interest Expense / Debt = 0.83% (Interest Expense 43.9m / Debt 5.29b)
Taxrate = 24.57% (38.9m / 158.3m)
NOPAT = 468.3m (EBIT 620.9m * (1 - 24.57%))
Current Ratio = 4.53 (Total Current Assets 2.72b / Total Current Liabilities 599.9m)
Debt / Equity = 1.40 (Debt 5.29b / totalStockholderEquity, last quarter 3.77b)
Debt / EBITDA = 4.78 (Net Debt 3.84b / EBITDA 802.1m)
Debt / FCF = 8.78 (Net Debt 3.84b / FCF TTM 436.8m)
Total Stockholder Equity = 3.24b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.72% (Net Income 274.2m / Total Assets 10.70b)
RoE = 8.45% (Net Income TTM 274.2m / Total Stockholder Equity 3.24b)
RoCE = 7.28% (EBIT 620.9m / Capital Employed (Equity 3.24b + L.T.Debt 5.29b))
RoIC = 5.53% (NOPAT 468.3m / Invested Capital 8.47b)
WACC = 4.64% (E(4.85b)/V(10.14b) * Re(9.03%) + D(5.29b)/V(10.14b) * Rd(0.83%) * (1-Tc(0.25)))
Discount Rate = 9.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.21%
[DCF Debug] Terminal Value 80.82% ; FCFF base≈314.2m ; Y1≈206.3m ; Y5≈94.1m
Fair Price DCF = N/A (negative equity: EV 3.00b - Net Debt 3.84b = -837.2m; debt exceeds intrinsic value)
EPS Correlation: 9.26 | EPS CAGR: -0.94% | SUE: -0.51 | # QB: 0
Revenue Correlation: -12.10 | Revenue CAGR: -17.58% | SUE: 0.80 | # QB: 0
EPS next Year (2026-12-31): EPS=4.38 | Chg30d=+0.046 | Revisions Net=+0 | Growth EPS=+72.9% | Growth Revenue=+15.0%